THE THERAPEUTIC CHALLENGE IN SYSTEMIC TREATMENT OF ADVANCED AND RECCURENT ENDOMETRIAL CANCER
https://doi.org/10.21294/1814-4861-2018-17-1-55-63
Abstract
More than 300 000 new cases of endometrial cancer (EC) are registered annually in the world. The prognosis for EC is determined by the stage of the disease. In Russia, stage III–IV EC is diagnosed in 16 % of patients, with the mortality rate in the first year of follow-up of 9.2 %. The management of recurrent/metastatic EC remains a challenging clinical problem. Hormone therapy and chemotherapy is effective in 30 % of patients, with median progression-free and overall survival rates of approximately 6 months and 12 months, respectively. The role of targeted therapy in the treatment of EC remains undefined. However, several studies demonstrated that combination of targeted therapy with chemotherapy resulted in significant improvement in overall survival of patients with advanced endometrial cancer. Published data on the study of checkpoint inhibitors for EC have shown promising results, however, further research is required to more completely understand how the immune system recognizes and eradicated cancer.
About the Authors
I. Y. Bazaeva
N.N. Blokhin National Medical Research Cancer Center
Russian Federation
Russian Federation
Irina Ya. Bazaeva - MD, PhD, Chemotherapy Department.
23, Kashirskoe shosse, 115478-Moscow
S. V. Khokhlova
N.N. Blokhin National Medical Research Cancer Center
Russian Federation
Russian Federation
Svetlana V. Khokhlova - MD, DSc, Senior Researcher, Chemotherapy Department, SPIN-code: 6009-4616. Author ID: 900117.
23, Kashirskoe shosse, 115478-Moscow
A. A. Fedenko
N.N. Blokhin National Medical Research Cancer Center
Russian Federation
Russian Federation
Alexandr A. Fedenko - MD, DSc, Head of Chemotherapy Department, SPIN-code: 9847-7668. Author ID: 823233.
23, Kashirskoe shosse, 115478-Moscow
References
1. Kaprin A.D., Starinsky V.V., Petrova G.V. Malignant tumors in Russia in 2015 (incidence and mortality). Moscow, 2017. 12. [in Russian]
2. Kaprin A.D., Starinsky V.V., Petrova G.V. Cancer care in Russia in 2015. Moscow, 2016. 25–26. [in Russian]
3. Kelley R.M., Baker W.H. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med. 1961 Feb 2; 264: 216–22. doi: 10.1056/NEJM196102022640503.
4. Thigpen J.T., Brady M.F., Alvarez R.D., Adelson M.D., Homesley H.D., Manetta A., Soper J.T., Given F.T. Oral Medroxyprogesterone Acetate in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A DoseResponse Study by the Gynecologic Oncology Group. J Clin Oncol, 1999; 17 (6): 1736–1744. doi: 10.1200/JCO.1999.17.6.1736.
5. Whitney C.W., Brunetto V.L., Zaino R.J., Lentz S.S., Sorosky J., Armstrong D.K., Lee R.B.; Gynecologic Oncology Group study. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol, 2004; 92 (1): 4–9.
6. Pandya K.J., Yeap B.Y., Weiner L.M., Krook J.E., Erban J.K., Schinella R.A., Davis T.E. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol 2001; 24 (1): 43–46.
7. Yang S., Xiao X., Jia Y., Liu X., Zhang Y., Wang X., Winters C.J., Devor E.J., Meng X., Thiel K.W., Leslie K.K. Epigenetic modification restores functional PR expression in endometrial cancer cells. Curr Pharm Des. 2014; 20 (11): 1874–80.
8. Rendina G.M., Donadio C., Fabri M., Mazzoni P., Nazzicone P. Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol, 1984; 17: 285–91.
9. Thigpen T., Brady M.F., Homesley H.D., Soper J.T., Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2001; 19 (2): 364–7. doi: 10.1200/JCO.2001.19.2.364.
10. Jeyarajah A.R., Gallagher C.J., Blake P.R., Oram D.H., Dowsett M., Fisher C., Oliver R.T.D. Long-term follow-up of gonadotrophinreleasing hormone analog treatment for recurrent endometrial cancer. Gynecol Oncol 1996; 63 (1): 47–52. doi: 10.1006/gyno.1996.0276.
11. Asbury R.F., Brunetto V.L., Lee R.B., Reid G., Rocereto T.F. Gynecologic Oncology Group. Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol 2002; 25 (6): 557–60.
12. Ma B.B., Oza A., Eisenhauer E., Stanimir G., Carey M., Chapman W., Latta E., Sidhu K., Powers J., Walsh W., Fyles A. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 2004; 14 (4): 650–8. doi: 10.1111/j.1048-891X.2004.14419.x.
13. Decruze S.B., Green J.A. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 2007; 17 (5): 964–978. doi: 10.1111/j.1525-1438.2007.00897.x.
14. Fleming G.F. Systemic chemotherapy for uterine carcinoma: Metastatic and adjuvant. J Clin Oncol 2007; 25 (31): 2983–2990. doi: 10.1200/JCO.2007.10.8431.
15. Thigpen J.T., Blessing J.A., DiSaia P.J., Yordan E., Carson L.F., Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol, 1994. 12 (7): 1408–14. doi: 10.1200/JCO.1994.12.7.1408.
16. Thigpen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A., Liao S. Phase III Trial of Doxorubicin With or Without Cisplatin in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2004, 22 (19): 3902–3908.
17. Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., Kline R., Burger R.A., Goodman A., Burks R.T. Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol, 2004, 22 (11): 2159–66. doi: 10.1200/JCO.2004.07.184.
18. Miller D., Filiaci V., Fleming G., Mannel R., Cohn D., Matsumoto T., Tewari K., DiSilvestro P., Pearl M., Zaino R. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2012; 125 (3): 771. doi: 10.1016/j.ygyno.2012.03.034.
19. McMeekin D.S., Filiaci V.L., Thigpen J.T., Gallion H.H., Fleming G.F., Rodgers W.H.; Gynecologic Oncology Group study. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: A Gynecologic Oncology Group study. Gynecol Oncol 2007; 106: 16–22. doi: 10.1016/j.ygyno.2007.04.032.
20. Moore K.N., Tian C., McMeekin S., Thigpen J.T., Randall M.E., Gallion H.H. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer? Cancer 2010; 116 (23): 5407–14. doi: 10.1002/cncr.25480.
21. Nagao S., Nishio S., Michimae H., Tanabe H., Okada S., Otsuki T., Tanioka M., Fujiwara K., Suzuki M., Kigawa J. Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study. Gynecol Oncol. 2013 Dec; 131 (3): 567–73. doi: 10.1016/j.ygyno.2013.09.021.
22. Tait D.L., Blessing J.A., Hoffman J.S., Moore K.N., Spirtos N.M., Lachance J.A., Rotmensch J., Miller D.S. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2011 Apr; 121 (1): 118–21.
23. Miller D.S., Blessing J.A., Drake R.D., Higgins R., McMeekin D.S., Puneky L.V., Krasner C.N. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology. Gynecol Oncol. 2009 Dec; 115 (3): 443–6. doi: 10.1016/j.ygyno.2009.09.004.
24. Dizon D.S., Blessing J.A., McMeekin D.S., Sharma S.K,. Disilvestro P., Alvarez R.D. Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P. J Clin Oncol. 2009 Jul 1; 27 (19): 3104–8. doi: 10.1200/JCO.2008.20.6995.
25. McMeekin S., Dizon D., Barter J., Scambia G., Manzyuk L., Lisyanskaya A., Oaknin A., Ringuette S., Mukhopadhyay P., Rosenberg J., Vergote I. Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. Gynecol Oncol. 2015 Jul; 138 (1): 18–23. doi: 10.1016/j.ygyno.2015.04.026.
26. Aghajanian C., Sill M.W., Darcy K.M., Greer B., McMeekin D.S., Rose P.G., Rotmensch J., Barnes M.N., Hanjani P., Leslie K.K. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011; 29 (16): 2259–65. doi: 10.1200/JCO.2010.32.6397.
27. Coleman R.L., Sill M.W., Lankes H.A., Fader A.N., Finkler N.J., Hoffman J.S., Rose P.G., Sutton G.P., Drescher C.W., McMeekin D.S., Hu W., Deavers M., Godwin A.K., Alpaugh R.K., Sood A.K. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2012; 127 (3): 538–43. doi: 10.1016/j.ygyno.2012.08.020.
28. Alvarez E.A., Brady W.E., Walker J.L., Rotmensch J., Zhou X.C., Kendrick J.E., Yamada S.D., Schilder J.M., Cohn D.E., Harrison C.R., Moore K.N., Aghajanian C. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129 (1): 22–7. doi: 10.1016/j.ygyno.2012.12.022.
29. Powell M.A., Sill M.W., Goodfellow P.J., Benbrook D.M., Lankes H.A., Leslie K.K., Jeske Y., Mannel R.S., Spillman M.A., Lee P.S., Hoffman J.S., McMeekin D.S., Pollock P.M. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014; 135 (1): 38–43. doi: 10.1016/j.ygyno.2014.07.083.
30. Bender D., Sill M.W., Lankes H.A., Reyes H.D., Darus C.J., Delmore J.E., Rotmensch J., Gray H.J., Mannel R.S., Schilder J.M., Hunter M.I., McCourt C.K., Samuelson M.I., Leslie K.K. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/ Gynecologic Oncology Group study. Gynecol Oncol. 2015 Sep; 138 (3): 507–12. doi: 10.1016/j.ygyno.2015.07.018.
31. Dizon D.S., Sill M.W., Schilder J.M., McGonigle K.F., Rahman Z., Miller D.S., Mutch D.G., Leslie K.K. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/ Gynecologic Oncology Group Study. Gynecol Oncol. 2014; 135 (3): 441–5. doi: 10.1016/j.ygyno.2014.10.001.
32. Makker V., Filiaci V.L., Chen L.M., Darus C.J., Kendrick J.E., Sutton G., Moxley K., Aghajanian C. Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptorfusion protein, for treatment of recurrent/persistent endometrial cancer: GOG 0229N. Gynecol Oncol. 2015 Jul; 138 (1): 24–9. doi: 10.1016/j.ygyno.2015.04.006.
33. Jeske Y.W., Ali S., Byron S.A., Gao F., Mannel R.S., Ghebre R.G., DiSilvestro P.A., Lele S.B., Pearl M.L., Schmidt A.P., Lankes H.A., Ramirez N.C., Rasty G., Powell M., Goodfellow P.J., Pollock P.M. FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 May; 145 (2): 366–373. doi: 10.1016/j.ygyno.2017.02.031.
34. Konecny G.E., Finkler N., Garcia A.A., Lorusso D., Lee P.S., Rocconi R.P., Fong P.C., Squires M., Mishra K., Upalawanna A., Wang Y., Kristeleit R. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. Lancet Oncol. 2015 Jun; 16 (6): 686–94. doi: 10.1016/S1470-2045(15)70159-2.
35. Lorusso D., Ferrandina G., Colombo N., Pignata S., Salutari V., Maltese G., Pisano C., Lapresa M., Savarese A., Tagliaferri P., Sorio R., Cinieri S., Breda E., Sabbatini R., Lepori S., Conte C., Cecere S.C., Raspagliesi F., Scambia G. Randomized phase II trial of carboplatinpaclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial. J Clin Oncol. 2015 May; 33 (15 suppl): 5502. doi: 10.1200/jco.2015.33.15_suppl.5502.
36. Aghajanian C., Filiaci V.L., Dizon D.S., Carlson J., Powell M.A., Secord A.A., Tewari K.S., Bender D., O’Malley D.M., Stuckey A., Rotmensch J., Levine D.A., Lankes H.A., Moore K.N. A randomized phase II study of paclitaxel/carboplatin/ bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/ bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. J Clin Oncol 2015; 33 (suppl): Abstract 5500.
37. Hussein Y.R., Weigelt B., Levine D.A., Schoolmeester J.K., Dao L.N., Balzer B.L., Liles G., Karlan B., Köbel M., Lee C.H., Soslow R.A. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod Pathol. 2015 Apr; 28 (4): 505–14. doi: 10.1038/modpathol.2014.143.
38. Rizvi N.A., Hellmann M.D., Snyder A., Kvistborg P., Makarov V., Havel J.J., Lee W., Yuan J., Wong P., Ho T.S., Miller M.L., Rekhtman N., Moreira A.L., Ibrahim F., Bruggeman C., Gasmi B., Zappasodi R., Maeda Y., Sander C., Garon E.B., Merghoub T., Wolchok J.D., Schumacher T.N., Chan T.A. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015 Apr 3; 348 (6230): 124–8. doi: 10.1126/science.aaa1348.
39. Howitt B.E., Shukla S.A., Sholl L.M., Ritterhouse L.L., Watkins J.C., Rodig S., Stover E., Strickland K.C., D’Andrea A.D., Wu C.J., Matulonis U.A., Konstantinopoulos P.A. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol. 2015 Dec; 1 (9): 1319–23. doi: 10.1001/jamaoncol.2015.2151.
40. Santin A.D., Bellone S., Buza N., Choi J., Schwartz P.E., Schlessinger J., Lifton R.P. Regression of chemotherapy-resistant Polymerase epsilon (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab. Clin Cancer Res. 2016 Dec 1; 22 (23): 5682–5687.
41. Diaz L.A., Marabelle A., Delord J.P., Shapira-Frommer R., Geva R., Peled N., Kim T.W., Andre T., Van Cutsem E., Guimbaud R., Jaeger D., Elez E., Yoshino T., Joe A.K., Lam B., Gause C.K., Pruitt S.K., Kang S.P., Le D.T. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. J Clin Oncology. 2017 May; 35 (15): 3071.
42. Ott P.A., Bang Y.J., Berton-Rigaud D., Elez E., Pishvaian M.J., Rugo H.S., Puzanov I., Mehnert J.M., Aung K.L., Lopez J., Carrigan M., Saraf S., Chen M., Soria J.C. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study J Clin Oncol. 2017 Aug 1; 35 (22): 2535–2541. doi: 10.1200/JCO.2017.72.5952.
Review
For citations:
Bazaeva I.Y., Khokhlova S.V., Fedenko A.A. THE THERAPEUTIC CHALLENGE IN SYSTEMIC TREATMENT OF ADVANCED AND RECCURENT ENDOMETRIAL CANCER. Siberian journal of oncology. 2018;17(1):55-63. (In Russ.) https://doi.org/10.21294/1814-4861-2018-17-1-55-63
Views:
1152
Email this article 
